NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir

Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice

(2018) Yuji Teraoka et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection

(2018) Akira Doi et al.   HEPATOLOGY

Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens

(2018) Norio Akuta et al.   JOURNAL OF MEDICAL VIROLOGY

Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures

(2018) Mitsutaka Osawa et al.   JOURNAL OF GASTROENTEROLOGY

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection

(2017) Hidenori Toyoda et al.   HEPATOLOGY

Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen

(2017) Edward J. Gane et al.   HEPATOLOGY

Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals

(2017) Hayato Kurata et al.   HEPATOLOGY RESEARCH

“Reversi-type virologic failure” involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline

(2017) Yoshihito Uchida et al.   HEPATOLOGY RESEARCH

Retreatment with sofosbuvir/ledipasvir with or without lead-in interferon-β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy

(2017) Hayato Uemura et al.   HEPATOLOGY RESEARCH

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis

(2017) Kazuaki Chayama et al.   JOURNAL OF GASTROENTEROLOGY

Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy

(2017) Goki Suda et al.   JOURNAL OF GASTROENTEROLOGY

Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

(2017) Hiromitsu Kumada et al.   JOURNAL OF GASTROENTEROLOGY

Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens

(2017) Norio Akuta et al.   JOURNAL OF MEDICAL VIROLOGY

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

(2017) Marc Bourlière et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism

(2016) Yoshihito Uchida et al.   HEPATOLOGY RESEARCH

Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing

(2015) Yoshihito Uchida et al.   JOURNAL OF GASTROENTEROLOGY

In VitroandIn VivoAntiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A

(2014) Preethi Krishnan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

(2014) Hiromitsu Kumada et al.   HEPATOLOGY

A Novel Simple Assay System to Quantify the Percent HCV-RNA Levels of NS5A Y93H Mutant Strains and Y93 Wild-Type Strains Relative to the Total HCV-RNA Levels to Determine the Indication for Antiviral Therapy with NS5A Inhibitors

(2014) Yoshihito Uchida et al.   PLoS One

Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885

(2013) Kelly A. Wong et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir

(2013) Chunfu Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System

(2010) R. A. Fridell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY